Lucius Elafibranor – Mua trực tuyến

EUR 823.33

1,800+ vendidos
Precio especial

Farmacia fisica en Hong Kong, 100% de autenticidad garantizada

Puntos clave

Elafibranor received accelerated approval in the United States in June 2024.

Garantias del servicio

Envio directo transfronterizoFarmacia autorizadaRevisado por farmaceuticoGarantia de autenticidad

Especificaciones

Especificacion
80mg*30 tabletas
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong

10000 disponibles

Informacion del producto

Nombre en ingles
Elafibranor
Nombre generico
Elafibranor

Especificaciones

Especificacion
80mg*30 tabletas
Fabricante
Lucius Pharmaceuticals
Envio
Hong Kong

Detalles completos

Indicaciones

Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.

Mecanismo de accion

Elafibranor Como funciona Como funciona ,

Dosis

2 , , / (2.1) 80 mg, (2.2) 2.1 IQIRVO IQIRVO [ Precauciones (5.1)] IQIRVO , [ Precauciones (5.3), (8.1, 8.3)] 2.2 IQIRVO 80 mg, [ (12.3)] 2.3 IQIRVO 4 4 , [ (7.2)]

Precauciones

5 Precauciones IQIRVO , (CPK) , IQIRVO 5.1 IQIRVO , 5.2

Package Insert

Ingredients

11 GFT1007 PPAR pH 1.2 6.8 , pH 7.5 , DMSO , C₂₂H₂₄O₄S, 384.49 g/mol, 2-(2,6- -4-{3-[4-( ) ]-3- -1- -1- } )-2- , IQIRVO 80 mg ,

Indications

Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.

Dosis

2 , , / (2.1) 80 mg, (2.2) 2.1 IQIRVO IQIRVO [ Precauciones (5.1)] IQIRVO , [ Precauciones (5.3), (8.1, 8.3)] 2.2 IQIRVO 80 mg, [ (12.3)] 2.3 IQIRVO 4 4 , [ (7.2)]

Precautions

5 Precauciones IQIRVO , (CPK) , IQIRVO 5.1 IQIRVO , 5.2

Use in Pregnancy and Lactation

8.1 , IQIRVO , elafibranor , / , IQIRVO ,

Clinical Pharmacology

12 12.1 Como funciona GFT1007 PPAR , PPAR-α PPAR-γ PPAR-δ , PBC PPAR-α PPAR-δ ,PPAR-δ 21 FGF21 CYP7A1 ,CYP7A1 PPAR ,elafibranor GFT1007 PPAR-α EC50 46 nM 14 nM,Em 0.05 0.05

Pharmacology and Toxicology

13 13.1 2 CD-1 , elafibranor 1 3 10 30 mg/kg/ , elafibranor GFT1007 AUC, 0.007 0.14 0.003 0.16 Sprague-Dawley , elafibranor 10 mg/kg/ elafibranor GFT1007 AUC 0.36 , 30 mg/kg/ elafibranor GFT1007 AUC 2.1 ,elafibranor

Clinical Studies

14 1 (NCT04526665) IQIRVO 161 (UDCA) (PBC) IQIRVO 80 mg (n=108) (n=53), , 52 , UDCA (ALP) ≥ (ULN) 1.67 , (TB) ≤ 2

Resenas del producto (13)

Filtro: Todas las resenas
4.8★★★★★
13 resenas de clientes10 compras verificadas
+o***e· 3周前
★★★★
+t***3· 1个月前
Compra verificada
★★★★★

Descripcion

Indicaciones

Indicated for adults with primary biliary cholangitis who have an inadequate response to ursodeoxycholic acid or cannot tolerate it.

Mecanismo de accion

Elafibranor Como funciona Como funciona ,

Dosis

2 , , / (2.1) 80 mg, (2.2) 2.1 IQIRVO IQIRVO [ Precauciones (5.1)] IQIRVO , [ Precauciones (5.3), (8.1, 8.3)] 2.2 IQIRVO 80 mg, [ (12.3)] 2.3 IQIRVO 4 4 , [ (7.2)]

Precauciones

5 Precauciones IQIRVO , (CPK) , IQIRVO 5.1 IQIRVO , 5.2